Business Wire

THALES

16.4.2024 09:01:32 CEST | Business Wire | Press release

Share
Bots Now Make Up Nearly Half of All Internet Traffic Globally

Thales, the cybersecurity leader that protects critical applications, APIs, and data, anywhere at scale, today announced the release of the 2024 Imperva Bad Bot Report, a global analysis of automated bot traffic across the internet. Nearly half (49.6%) of all internet traffic came from bots in 2023—a 2% increase over the previous year, and the highest level Imperva has reported since it began monitoring automated traffic in 2013.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416225637/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

For the fifth consecutive year, the proportion of web traffic associated with bad bots grew to 32% in 2023, up from 30.2% in 2022, while traffic from human users decreased to 50.4%. Automated traffic is costing organizations billions (USD) annually due to attacks on websites, APIs, and applications.

“Bots are one of the most pervasive and growing threats facing every industry,” says Nanhi Singh, General Manager, Application Security at Imperva, a Thales company. “From simple web scraping to malicious account takeover, spam, and denial of service, bots negatively impact an organization’s bottom line by degrading online services and requiring more investment in infrastructure and customer support. Organizations must proactively address the threat of bad bots as attackers sharpen their focus on API-related abuses that can lead to account compromise or data exfiltration.”

Key trends identified in the 2024 Imperva Bad Bot Report include:

  • Global average of bad bot traffic reached 32%: Ireland (71%), Germany (67.5%), and Mexico (42.8%), saw the highest levels of bad bot traffic in 2023. The US also saw a slightly higher ratio of bad bot traffic at 35.4% compared to 2022 (32.1%).
  • Growing use of generative AI connected to the rise in simple bots: Rapid adoption of generative AI and large language models (LLMs) resulted in the volume of simple bots increasing to 39.6% in 2023, up from 33.4% in 2022. The technology uses web scraping bots and automated crawlers to feed training models, while enabling nontechnical users to write automated scripts for their own use.
  • Account takeover is a persistent business risk: Account takeover (ATO) attacks increased 10% in 2023, compared to the same period in the prior year. Notably, 44% of all ATO attacks targeted API endpoints, compared to 35% in 2022. Of all login attempts across the internet, 11% were associated with account takeover. The industries that saw the highest volume of ATO attacks in 2023 were Financial Services (36.8%), Travel (11.5%), and Business Services (8%).
  • APIs are a popular vector for attack: Automated threats caused a significant 30% of API attacks in 2023. Among them, 17% were bad bots exploiting business logic vulnerabilities—a flaw within the API’s design and implementation that allows attackers to manipulate legitimate functionality and gain access to sensitive data or user accounts. Cybercriminals use automated bots to find and exploit APIs, which act as a direct pathway to sensitive data, making them a prime target for business logic abuse.
  • Every industry has a bot problem: For a second consecutive year, Gaming (57.2%) saw the largest proportion of bad bot traffic. Meanwhile, Retail (24.4%), Travel (20.7%), and Financial Services (15.7%) experienced the highest volume of bot attacks. The proportion of advanced bad bots, those that closely mimic human behavior and evade defenses, was highest on Law & Government (75.8%), Entertainment (70.8%), and Financial Services (67.1%) websites.
  • Bad bot traffic originating from residential ISPs grows to 25.8%: Early bad bot evasion techniques relied on masquerading as a user agent (browser) commonly used by legitimate human users. Bad bots masquerading as mobile user agents accounted for 44.8% of all bad bot traffic in the past year, up from 28.1% just five years ago. Sophisticated actors combine mobile user agents with the use of residential or mobile ISPs. Residential proxies allow bot operators to evade detection by making it appear as if the origin of the traffic is a legitimate, ISP-assigned residential IP address.

“Automated bots will soon surpass the proportion of internet traffic coming from humans, changing the way that organizations approach building and protecting their websites and applications,” continued Singh. “As more AI-enabled tools are introduced, bots will become omnipresent. Organizations must invest in bot management and API security tools to manage the threat from malicious, automated traffic.”

Additional Information:

  • Download a copy of the 2024 Imperva Bad Bot Report for additional insights.
  • See how Imperva Advanced Bot Protection, API Security, and Client-Side Protection can protect websites, mobile applications, and APIs from automated attacks and fraud without affecting the flow of business-critical traffic.
  • Read the Imperva Blog for the latest product and solution news, and threat intelligence from Imperva Threat Research.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

* These figures exclude the ground transportation business, which is being divested

PLEASE VISIT

Thales Group

Cloud Protection & Licensing Solutions | Thales Group

Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240416225637/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye